In-practice Evaluation of Atacand 16mg Antihypertensive Effect
NCT00802542 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 400
Last updated 2010-12-03
Summary
The purpose of this study is to prove in practice the effectiveness of Atacand 16 mg in reducing blood pressure after 4 weeks of administration and the importance of administration of adequate doses
Conditions
- Essential Hypertension
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Agrita Hartmane · AstraZeneca
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2008-11-30
- Primary Completion
- 2009-01-31
- Completion
- 2009-01-31
Countries
- Latvia
Study Locations
More Related Trials
-
COmpliance and Efficacy in Mono and Combination Tablet Study ATacand/Atacand Plus
NCT00526279 ·Status: COMPLETED
-
High Doses of Candesartan Cilexetil on the Reduction of Proteinuria
NCT00242346 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of Angiotensin Converting Enzyme (ACE) Inhibitors Versus Candesartan in Reducing Cardiovascular Events in Primary Treatment of Hypertension
NCT01152567 ·Status: COMPLETED
-
Atacand Dose Range Finding Study in Pediatric Subjects 6 to <17 Years of Age
NCT00244634 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Candesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control
NCT02521233 ·Status: WITHDRAWN ·Phase: PHASE3
-
Efficacy Observational Study of Candesartan Cilexetil on Hypertensive Patients
NCT00573742 ·Status: COMPLETED
-
TROPHY - Candesartan Cilexetil Long-term Hypertension Prevention Trial
NCT00227318 ·Status: COMPLETED ·Phase: PHASE3
-
Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo
NCT00434967 ·Status: COMPLETED ·Phase: PHASE3
-
Candesartan Effectiveness Study in Pro-B Type Natriuretic Peptides (BNP)
NCT00348686 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension
NCT00696241 ·Status: COMPLETED ·Phase: PHASE3
-
Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Alternative)
NCT00634400 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Candesartan Associated With Chlorthalidone Versus Losartan Associated With Hydrochlorothiazide (Hyzaar®) in Essential Hypertension Control
NCT02521246 ·Status: WITHDRAWN ·Phase: PHASE3
-
The Real-Life Efficacy and Safety of Telmisartan in Patients With Arterial Hypertension
NCT00471003 ·Status: COMPLETED
-
The Potential of Candesartan to Retard the Progression of Aortic Stenosis
NCT00699452 ·Status: UNKNOWN ·Phase: PHASE3
-
Scandinavian Candesartan Acute Stroke Trial (SCAST)
NCT00120003 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Candesartan Cilexetil Plus Hydrochlorothiazide in Subjects With Severe Hypertension
NCT01012479 ·Status: COMPLETED ·Phase: PHASE4
-
CHANCE - Candesartan in Hypertrophic Cardiomyopathy
NCT00430833 ·Status: UNKNOWN ·Phase: PHASE2
-
Antihypertensive Efficacy and Safety of Candesartan/HCT 32/12.5 and 32/25 mg in Comparison With Candesartan 32 mg
NCT00383929 ·Status: COMPLETED ·Phase: PHASE3
-
Observation of Therapy With Micardis® (Telmisartan) in Patients With Essential Hypertension in Hospitals
NCT02238262 ·Status: COMPLETED
-
Changes After Angiotensin Converting Enzyme (ACE) Inhibitor Replacement by Angiotensin II Receptor Type I (AT1) Blocker
NCT01444833 ·Status: UNKNOWN ·Phase: NA
-
Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Hypertension and LVH
NCT00607633 ·Status: COMPLETED
-
A Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive Patients With Metabolic Syndrome
NCT05843162 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy, Safety, & Pharmacokinetics of Candesartan Cilexetil in Hypertensive Paediatric Subjects 6 to < 17 Years of Age
NCT00244595 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Study to Evaluate the Antihypertensive Efficacy and Changes of Neurohormonal Markers of Fimasartan and Atenolol With Exaggerated Blood Pressure Response During Exercise in Essential Hypertensive Patients
NCT01736488 ·Status: COMPLETED ·Phase: PHASE4
-
Micardis®. Observational Study in Patients With Essential Hypertension
NCT02200094 ·Status: COMPLETED